“One of the most important considerations before switching HIV patients to injectable long-acting cabotegravir/rilpivirine [CAB/RPV LA; Cabenuva, ViiV Healthcare] is

Out of an estimated 104,000 people offered HIV preexposure prophylaxis (PrEP) to protect themselves from HIV, just 14 people acquired